A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Clicks: 180
ID: 112758
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #258 of 1,084 articles by views in clinical infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Imipenem/cilastatin/relebactam was noninferior to piperacillin/tazobactam for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VAB
Reference Key
ivanclinicala Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Titov, Ivan;Wunderink, Richard G;Roquilly, Antoine;Rodríguez Gonzalez, Daniel;David-Wang, Aileen;Boucher, Helen W;Kaye, Keith S;Losada, Maria C;Du, Jiejun;Tipping, Robert;Rizk, Matthew L;Patel, Munjal;Brown, Michelle L;Young, Katherine;Kartsonis, Nicholas A;Butterton, Joan R;Paschke, Amanda;Chen, Luke F;
Journal clinical infectious diseases
Year Year not found
DOI
DOI not found
URL
https://doi.org/10.1093/cid/ciaa803
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.